The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis
| Autor: | Renelene Macabeo, Rosemarie Ramirez-Ragasa, Noemi S. Pestaño, Bernadette Tumanan-Mendoza, Felix Eduardo R. Punzalan, Rafael R Castillo, Marie A. Barrientos-Regala |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Allopurinol Blood Pressure Hyperuricemia 030204 cardiovascular system & hematology Risk Assessment Gout Suppressants 03 medical and health sciences Febuxostat 0302 clinical medicine Risk Factors Internal medicine medicine Humans Myocardial infarction Risk factor Stroke Aged Randomized Controlled Trials as Topic Pharmacology business.industry Middle Aged medicine.disease Uric Acid Treatment Outcome 030104 developmental biology Blood pressure Hypertension Female Cardiology and Cardiovascular Medicine business Biomarkers Mace medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology. 76:461-471 |
| ISSN: | 0160-2446 |
| Popis: | Increased uric acid levels have been known to be associated with different cardiovascular and renal diseases. Over the past few years, several studies have examined the role of urate-lowering therapy (ULT) in hypertension and major adverse cardiac events (MACE) and suggest a potential role of elevated serum uric acid as an independent cardiovascular risk factor. This meta-analysis was done to determine the association of 2 ULTs commonly used in clinical practice (febuxostat vs. allopurinol) on hypertension and MACE and resolve the conflicting results of the outcomes of earlier studies. Randomized controlled trials comparing febuxostat versus allopurinol published with outcomes on blood pressure, all-cause mortality, myocardial infarction (MI), and stroke were searched through PubMed, Google Scholar, and Cochrane database. A total of 10 studies were subsequently included in the meta-analysis. Pooled analysis of the mean differences (MD) were done for the outcomes on blood pressure (systolic and diastolic) and risk ratios (RRs) for the outcomes on MACE with corresponding 95% confidence intervals (CIs). Pooled analysis of studies on hyperuricemic patients showed that febuxostat 40 mg has no significant difference compared with allopurinol 100/300 mg with respect to diastolic (MD, -0.56 with 95% CI of -4.28 to 3.15) and systolic blood pressure (MD, 0.30 with 95% CI of -3.33 to 3.93). No significant differences were also noted on all-cause mortality (RR, 1.18 with 95% CI of 0.99-1.41), MI (RR, 0.92 with 95% CI of 0.72-1.18), and stroke (RR, 1.05 with 95% CI of 0.77-1.43). The results of this meta-analysis showed that the 2 ULTs (febuxostat vs. allopurinol) have no significant association with respect to blood pressure among adult patients with hyperuricemia. No significant association was also noted of either ULT with all-cause mortality, MI, and stroke. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|